



File No: BIO/CT/24/000003

Dated 09-Jul-2024

To,

M/s Intas Pharmaceuticals Ltd,
Corporate House, Near Sola Bridge S.G. Highway,
Thaltej Ahmedabad (India) - 380054.

Subject: Application for grant of permission to conduct Phase III clinical trial titled "A prospective, randomized, open-label, parallel group, active-controlled, multicenter, phase 3 study to evaluate the efficacy, safety, immunogenicity and pharmacokinetics of proposed Trastuzumab Emtansine biosimilar compared with Kadcyla® in HER2-positive unresectable locally advanced or metastatic breast cancer patients who have received prior treatment with Trastuzumab and a Taxane." as per Protocol No.: 0198-23, Version: 1.1, Date: 03-January-2024– regarding

Ref.: Your Application No BIO/CT04/FF/2024/41381 dated 16-01-2024

Sir,

With reference to your Application No. BIO/CT04/FF/2024/41381 dated 16-01-2024, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.
- (XVIII) Clinical Study report (CSR) shall be submitted to this office after completion of the trial

RAJEEV SINGH
RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: cn=RAJEEV SINGH RAGHUVANSHI, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION,
2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11b680a9
1f08773480400a43ee361b, postalCode=110002, st=Delhi,
serialNumber=657f5e47d940985d8f03bcd902d0e1fe73cfa1
2a1a126e994fa5701124a19013, cn=RAJEEV SINGH
RAGHUVANSHI
Date: 2024.07.09 15:28:54 +05'30'

Yours faithfully

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s Intas Pharmaceuticals Ltd, Corporate House, Near Sola Bridge S.G. Highway, Thaltej Ahmedabad (India) - 380054 Telephone No.: 07939837000 FAX: 912717661106 to conduct Phase III clinical trial entitled " **A prospective, randomized, open-label, parallel group, active-controlled, multicenter, phase 3 study to evaluate the efficacy, safety, immunogenicity and pharmacokinetics of proposed Trastuzumab Emtansine biosimilar compared with Kadcyła® in HER2-positive unresectable locally advanced or metastatic breast cancer patients who have received prior treatment with Trastuzumab and a Taxane** " as per Protocol No: 0198-23, Version: 1.1, Date: 03-January-2024 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 09-July-2024

**RAJEEV SINGH
RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: cn=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL
ORGANISATION,
2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11b680a91f
08773480400a43ee361b, postalCode=110002, st=Delhi,
serialNumber=657f5e47d940985d803bdc902d0e1fe73cfa12a
1a126ca946a5701124a19013, cn=RAJEEV SINGH
RAGHUVANSHI
Date: 2024.07.09 15:29:04 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Trastuzumab Emtansine Powder for Concentrate for Solution for Infusion 100 mg/Vial and 160 mg/Vial	
Dosage form:	Powder for concentrate for solution for infusion	
Therapeutic Class	Anticancer	
Composition:	Each vials contains:	
	Name of Ingredients	Quantity in each vial per ml
	Trastuzumab Emtansine IHS	20 mg/ml
	Succinic acid USP, BP/Ph. Eur., JP	1.18 mg/mL (10 mM)
	Sucrose USP, Ph. Eur.	60 mg/mL (6 % w/v)
	Polysorbate-20 USP, Ph. Eur., IP	0.20 mg/mL (0.02 % w/v)
	Sodium hydroxide USP, Ph. Eur., IP	q.s. to pH 5.0
	Water for Injection USP, Ph. Eur., IP	QS to 1 ml
Indications:	<p>(1) T-DM1 is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.</p> <p>(2) T-DM1 is indicated for the treatment of adult patients with HER2- positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:</p> <ol style="list-style-type: none"> i. Received prior therapy for locally advanced or metastatic disease, or ii. Developed disease recurrence during or within six months of completing adjuvant therapy. 	

Details of clinical trial site:

Names and address of clinical trial site	Ethics committee details	Name of Investigator
HCG City Cancer Centre, #33-25-33, Ch. Venkatakrishnayya Street, Suryaraopet, Vijaywada - 520002, Andhra Pradesh, India.	Institutional Ethics Committee- HCG Curie City Cancer Centre, 44-1-1/3, Padavalarevu, Gunadala, Vijayawada, Andhra Pradesh - 520004, India. EC Reg. No ECR/869/Inst/AP/2016/RR-19	Dr. K. Lakshmi Priyadarshini
Sankalp Speciality Hospital, Dhanvantari Marg, Vallabh Nagar, Behind Chhan Hotel , Mumbai Agra Highway, Mumbai Naka, Nashik-422009, Maharashtra, India.	Navsanjeevani Hospital Ethics Committee Navsanjeevani Hospitals (Sankalp Speciality Healthcare Pvt. Ltd.) Plot No.8, Motkari Nagar, Tidke colony, Mumbai Naka, Nashik, Maharashtra-422002, India. EC Reg. No ECR/1036/Inst/MH/2018/RR-21.	Dr. Nemade Bhushan Tapiram
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre, Nehru Nagar, Belagavi -590010, Karnataka, India.	Institutional Ethics Committee, KLE University KLE University KLE Dr.PK Hospital and MRC Nehru Nagar, Belagavi (Belgaum), Karnataka - 590010 India. EC Reg. No ECR/211/Inst/KA/2013/RR-19	Dr. Maheshkumar Kalloli
Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, 52/B, Shankar Nagar, Main Road, Amravati 444606	Amravati ethics committee sujan surgical cancer hospital and research,52/b Shankar nagar, main road, Amravati, Maharashtra - 44606 India. EC Reg. No ECR/432/Inst/MH/2013/RR-19	Dr. Rajendrasingh Arora
Shankus Hospitals Private Limited, Shankus Medicity 214.B/h. Divine Child School, Near Shankus Water park, Baliyasan, Ta & Dist. Mehsana, Gujrat, 382732, India.	IEC - Shankus Hospitals B/H Divine Child School, Opp.Shankuz Waterpark, Baliyasan, Mehsana, Gujarat - 384435 India. EC Reg. No ECR/1615/Inst/GJ/2021	Dr. Nirali Trivedi
Kiran Hospital Multi Super Speciality Hospital & Research Centre, Near Sumul Dairy, Surat-395004- Gujrat, India.	Kiran Hospital Ethics Committee Near Sumul Dairy, Surat- 395004, Gujarat, India. EC Reg. No. ECR/1029/Inst/GJ/2018/RR-21	Dr. Priyal Bharatkumar Dhameliya

MNJ Institute of Oncology & Regional Cancer Centre, 3rd floor, Clinical trial room No. 11, Red Hills, Hyderabad- 500004, Telangana, India.	MNJIORCC Ethics Committee MNJ Institute of Oncology and RCC Lakdikapool Red Hills Hyderabad, Telangana - 500004 India EC Reg. No. ECR/227/Inst/AP/2013/RR-19	Dr. P. K. Chaithanya
Narayana Multispeciality Hospital, Unit of Narayana Hrudayalaya Limited, Opp. Police station, rakhiyal Cross Road, Ahmedabad-380023, Gujarat, India.	Sangini Hospital Ethics Committee Santorini Square, B/H Abhishree Complex, Opp. Star Bazar, Nr Jodhpur Cross Roads, Satellite, Ahmedabad, Gujarat - 380015 India. EC Reg. No. ECR/147/Inst/GJ/2013/RR-19	Dr. Rushabh Kothari
Sterling Hospital, Unit of Sterling Addlife India Pvt. Ltd., Plot No. 251, 150 Feet Ring Road, Nr. Raiya Circle, Rajkot - 360007, Gujarat, India.	Sterling Institutional Ethics Committee Sterling Hospital, Plot No. 251, 150 ft. Ring Road Near Raiya Circle, Nanavati Chowk Rajkot, Gujarat - 360007 EC Reg. No. ECR/1330/Inst/GJ/2019	Dr. Aditi Harsh Thanky
Oncoville Cancer Hospital & Research Centre, No. 4, 80 ft. Road, 7th Block, Nagarbhavi, 2nd Stage, Bangalore - 560072, Karnataka, India.	Institutional Ethics Committee of OCH and RC, Oncoville Cancer Hospital And Research Centre, No.4, 80 Ft. Road, 7th Block, Nagarbhavi 2nd Stage, Bengaluru (Bangalore), Karnataka - 560072 India. EC Reg. No. ECR/1490/Inst/KA/2021	Dr. Anil Kumar M.R.

